At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 198 enrolled
Drug / intervention
AGN-151586 +1 moredrug
Likely dose
Not stated in record
Key inclusion· 1
- ✓Female participants willing to minimize pregnancy risk for duration of study and follow-up (at least 10 weeks after study intervention)
Key exclusion· 10
- ✕Known immunization or hypersensitivity to any botulinum neurotoxin serotype
- ✕Neuromuscular disorders: diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any condition that might interfere with neuromuscular function
- ✕Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or inability to substantially lessen facial lines by physically spreading them apart
- ✕Any brow or eyelid ptosis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines
In Brief
A Phase 2 clinical trial evaluating AGN-151586 and Placebo for Glabellar Lines. Completed, enrolled 198 participants across 9 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Lines
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartSep 2019
Primary CompletionSep 2020
TodayJul 2026
First PostedSep 19, 2019
Enrollment StartSep 26, 2019
Primary CompletionSep 9, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.8 years ago
Interventions
AGN-151586drug
AGN-151586 solution for injection.
Placebodrug
Placebo solution for injection.